Qureight Appointed Imaging CRO for Celea's Phase 3 SURPASS-IPF Trial
Qureight has been appointed imaging CRO for Celea Therapeutics' Phase 3 SURPASS-IPF trial, a 52-week study comparing deupirfenidone with pirfenidone in idiopathic pulmonary fibrosis. The contract follows Qureight's work analysing CT scans on Celea's Phase 2b ELEVATE-IPF trial.